Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease
- 1 April 2018
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 150, 87-101
Abstract
No abstract availableKeywords
Funding Information
- Department of Biotechnology (DBT), New Delhi, IndiaDepartment of Biotechnology (DBT), New Delhi, India (BT/PR9624/MED/30/1253/2013)
This publication has 42 references indexed in Scilit:
- Curcumin: a potential candidate for matrix metalloproteinase inhibitorsExpert Opinion on Therapeutic Targets, 2012
- Status of research on MMPs in IndiaExpert Opinion on Therapeutic Targets, 2011
- Genesis and development of DPPH method of antioxidant assayJournal of Food Science and Technology, 2011
- Amyloid-β-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's diseaseMolecular Neurodegeneration, 2010
- The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristaeProceedings of the National Academy of Sciences, 2008
- Triple-Transgenic Model of Alzheimer's Disease with Plaques and TanglesNeuron, 2003
- Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell LinesExperimental Neurology, 2000
- Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain MitochondriaJournal of Neurochemistry, 1999
- Impairment of one-trial passive avoidance learning in mice by scopolamine, scopolamine methylbromide, and physostigmineInternational Journal of Neuropharmacology, 1967
- TOSYLATED PEPTIDES AND p-NITROPHENYL ESTERSCanadian Journal of Chemistry, 1963